130 related articles for article (PubMed ID: 12057654)
1. Non-thiol farnesyltransferase inhibitors: utilization of an aryl binding site by 5-arylacryloylaminobenzophenones.
Mitsch A; Böhm M; Wissner P; Sattler I; Schlitzer M
Bioorg Med Chem; 2002 Aug; 10(8):2657-62. PubMed ID: 12057654
[TBL] [Abstract][Full Text] [Related]
2. Non-thiol farnesyltransferase inhibitors: utilization of the far aryl binding site by 5-cinnamoylaminobenzophenones.
Mitsch A; Wissner P; Böhm M; Silber K; Klebe G; Sattler I; Schlitzer M
Arch Pharm (Weinheim); 2004 Sep; 337(9):493-501. PubMed ID: 15362122
[TBL] [Abstract][Full Text] [Related]
3. Non-thiol farnesyltransferase inhibitors: utilization of the near aryl binding site by 5-arylacetylaminobenzophenones.
Mitsch A; Böhm M; Sattler I; Schlitzer M
Arch Pharm (Weinheim); 2004 Apr; 337(4):213-8. PubMed ID: 15065081
[TBL] [Abstract][Full Text] [Related]
4. Non-thiol farnesyltransferase inhibitors: structure-activity relationships of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
Schlitzer M; Böhm M; Sattler I
Bioorg Med Chem; 2002 Mar; 10(3):615-20. PubMed ID: 11814849
[TBL] [Abstract][Full Text] [Related]
5. Structure based design of benzophenone-based non-thiol farnesyltransferase inhibitors.
Schlitzer M
Curr Pharm Des; 2002; 8(19):1713-22. PubMed ID: 12171543
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, molecular modeling, and structure-activity relationship of benzophenone-based CAAX-peptidomimetic farnesyltransferase inhibitors.
Sakowski J; Böhm M; Sattler I; Dahse HM; Schlitzer M
J Med Chem; 2001 Aug; 44(18):2886-99. PubMed ID: 11520197
[TBL] [Abstract][Full Text] [Related]
7. Non-thiol farnesyltransferase inhibitors: structure-activity relationships of aralkylsubstituted benzophenones.
Mitsch A; Wissner P; Sattler I; Schlitzer M
Arch Pharm (Weinheim); 2001 Feb; 334(2):40-4. PubMed ID: 11268773
[TBL] [Abstract][Full Text] [Related]
8. Non-thiol farnesyltransferase inhibitors: utilization of the far aryl binding site by arylthienylacryloylaminobenzophenones.
Mitsch A; Altenkämper M; Sattler I; Schlitzer M
Arch Pharm (Weinheim); 2005 Jan; 338(1):9-17. PubMed ID: 15674808
[TBL] [Abstract][Full Text] [Related]
9. Non-thiol farnesyltransferase inhibitors: FTase-inhibition and cellular activity of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
Mitsch A; Bergemann S; Gust R; Sattler I; Schlitzer M
Arch Pharm (Weinheim); 2003 Jul; 336(4-5):242-50. PubMed ID: 12916059
[TBL] [Abstract][Full Text] [Related]
10. Exploration of novel aryl binding sites of farnesyltransferase using molecular modeling and benzophenone-based farnesyltransferase inhibitors.
Böhm M; Mitsch A; Wissner P; Sattler I; Schlitzer M
J Med Chem; 2001 Sep; 44(19):3117-24. PubMed ID: 11543680
[TBL] [Abstract][Full Text] [Related]
11. Non-thiol farnesyltransferase inhibitors: N-(4-Acylamino-3-benzoylphenyl)-4-nitrocinnamic acid amides.
Sakowski J; Sattler I; Schlitzer M
Bioorg Med Chem; 2002 Feb; 10(2):233-9. PubMed ID: 11741771
[TBL] [Abstract][Full Text] [Related]
12. Non-thiol farnesyltransferase inhibitors: N-(4-tolylacetylamino-3-benzoylphenyl)-3-arylfurylacrylic acid amides.
Mitsch A; Wissner P; Silber K; Haebel P; Sattler I; Klebe G; Schlitzer M
Bioorg Med Chem; 2004 Sep; 12(17):4585-600. PubMed ID: 15358286
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of farnesyltransferase: 5-arylacryloylaminobenzophenones show antimalarial activity.
Wiesner J; Ortmann R; Mitsch A; Wissner P; Sattler I; Jomaa H; Schlitzer M
Pharmazie; 2003 Apr; 58(4):289-90. PubMed ID: 12749417
[No Abstract] [Full Text] [Related]
14. Non-thiol farnesyltransferase inhibitors: N-(4-acylamino-3-benzoylphenyl)-3-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides.
Kettler K; Sakowski J; Silber K; Sattler I; Klebe G; Schlitzer M
Bioorg Med Chem; 2003 Apr; 11(7):1521-30. PubMed ID: 12705292
[TBL] [Abstract][Full Text] [Related]
15. Non-thiol farnesyltransferase inhibitors: the concept of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
Schlitzer M; Sattler I
Eur J Med Chem; 2000; 35(7-8):721-6. PubMed ID: 10960188
[TBL] [Abstract][Full Text] [Related]
16. Non-thiol farnesyltransferase inhibitors: evaluation of different AA(X)-peptidomimetic substructures in combination with arylic cysteine replacements.
Sakowski J; Böhm M; Sattler I; Schlitzer M
Arch Pharm (Weinheim); 2002 Apr; 335(4):135-42. PubMed ID: 12112033
[TBL] [Abstract][Full Text] [Related]
17. Non-peptidic, non-prenylic bisubstrate farnesyltransferase inhibitors. Part 3: structural requirements of the central moiety for farnesyltransferase inhibitory activity.
Schlitzer M; Böhm M; Sattler I
Bioorg Med Chem; 2000 Oct; 8(10):2399-406. PubMed ID: 11058034
[TBL] [Abstract][Full Text] [Related]
18. Development of tripeptidyl farnesyltransferase inhibitors.
Lee HY; Sohn JH; Kwon BM
Bioorg Med Chem Lett; 2002 Jun; 12(12):1599-602. PubMed ID: 12039571
[TBL] [Abstract][Full Text] [Related]
19. Different amino acid replacements in CAAX-tetrapeptide based peptidomimetic farnesyltransferase inhibitors.
Schlitzer M; Sattler I; Dahse HM
Arch Pharm (Weinheim); 1999 Apr; 332(4):124-32. PubMed ID: 10327885
[TBL] [Abstract][Full Text] [Related]
20. Potent, non-thiol inhibitors of farnesyltransferase.
Breslin MJ; deSolms SJ; Giuliani EA; Stokker GE; Graham SL; Pompliano DL; Mosser SD; Hamilton KA; Hutchinson JH
Bioorg Med Chem Lett; 1998 Dec; 8(23):3311-6. PubMed ID: 9873725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
